CANCER TREATMENT CENTERS OF AMERICA RECEIVES 2021 PRESS GANEY GUARDIAN OF EXCELLENCE AWARD®

Article

Comprehensive cancer centers in Chicago and Atlanta earn national distinction as top performers in patient experience.

Boca Raton, Fla., December 16, 2021, Cancer Treatment Centers of America® (CTCA) is pleased to announce its hospitals in Atlanta and Chicago have been named 2021 Guardian of Excellence Award® winners by Press Ganey, the national leader in healthcare consumer and workforce engagement. Press Ganey recognizes CTCA® as a top-performing healthcare organization, with its hospital in Georgia being one of two in the state and its hospital in Illinois being one of five in the state, that achieved the 95th percentile or above for performance in patient experience.

The Press Ganey Guardian of Excellence Award® is a preeminent, competitive achievement for leading healthcare organizations. Presented annually, the award applauds hospitals and health systems that consistently sustained performance in the top 5% of all Press Ganey clients.

“Press Ganey is honored to recognize multiple CTCA hospitals among the nation’s leaders in patient experience,” said Patrick T. Ryan, chairman and chief executive officer, Press Ganey. “This award reflects an unwavering commitment to earn the trust and loyalty of patients throughout unimaginable challenges. We are humbled by CTCA’s incredible efforts, and their ability to adapt to imperatives of COVID-19 on top of the increasing demand for consumerism in healthcare.”

The CTCA Atlanta and Chicago teams initiated a number of best practices, which were instrumental in the hospitals achieving consistently sustained performance within the top five percent of all Press Ganey clients in the category of patient experience based on inpatient HCAHPS (Hospital Consumer Assessment of Healthcare Providers and Systems) survey results. These initiatives included monthly patient satisfaction meetings to review patient comments and develop action plans to address opportunities for improvement. Additionally, the teams implemented a cadence of follow up phone calls from leadership with patients and caregivers to address survey comments, utilization of technology to improve patient communication and engagement, hourly rounding by nursing staff and daily leader rounding, which allowed for real-time issue resolution and enhanced communication between departments.

“This recognition reflects our dedication to not only delivering highly skilled patient-centered oncology care across the cancer care continuum, but also the commitment of our employees who worked tirelessly throughout a chaotic year to positively impact the lives of everyone we serve,” said Pat Basu, MD, MBA, President and CEO of CTCA. Dr. Basu further explained that Press Ganey’s Guardian of Excellence Award® demonstrates that the Atlanta and Chicago communities can receive top-rated care close to home.

About Press Ganey

Press Ganey pioneered the health care performance improvement movement 35 years ago. Today Press Ganey offers an integrated suite of solutions that enable enterprise transformation across the patient journey. Delivered through a cutting-edge digital platform built on a foundation of data security, Press Ganey solutions address safety, clinical excellence, patient experience, and workforce engagement. The company works with more than 41,000 health care facilities in its mission to reduce patient suffering and enhance caregiver resilience to improve the overall safety, quality, and experience of care.

About Cancer Treatment Centers of America
Cancer Treatment Centers of America® (CTCA) is a national oncology network of hospitals and outpatient care centers offering an integrated approach that combines surgery, radiation, chemotherapy, immunotherapy and advancements in precision medicine with supportive therapies to manage side effects and enhance quality of life during treatment and into survivorship. CTCA®publishes treatment results bi-annually including patient experience, length of life, quality of life, patient safety and quality of care. CTCA also offers qualified patients a range of clinical trials that may reveal new treatment options supported by scientific and investigational research. CTCA patient satisfaction scores consistently rank among the highest for all cancer care providers in the country. Visit cancercenter.com for more information.

Media Contact:

Cancer Treatment Centers of America

Samantha Paz

samantha.paz@ctca-hope.com
215-537-7080

Press Ganey

Sarah Adell, Director of Communications

815.499.5122

Sarah.Adell@PressGaney.com

Recent Videos
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
First-degree relatives of patients who passed away from pancreatic cancer should be genetically tested to identify their risk for the disease.
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent care vs incarcerated patients.
A collaboration between the Connecticut Departments of Health and Corrections and the COPPER Center aimed to improve outcomes among incarcerated patients.
Computational models help researchers anticipate how ADCs may behave in later lines of development, while they are still in the early stages.
ADC payloads with high levels of potency can sometimes lead to higher levels of toxicity, which can eliminate the therapeutic window for patients with cancer.
According to Greg Thurber, PhD, target-mediated uptake is the biggest driver of efficacy for antibody-drug conjugates as a cancer treatment.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to expect at the 43rd Annual Chemotherapy Foundation Symposium, such as new chemotherapeutics and targeted therapies.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Related Content
Rising cancer diagnoses in the US highlight urgent needs for improved oncology education, workforce distribution, and care infrastructure, especially in rural areas.

A Decline in the US Oncology Workforce: What Will the Next Decade Bring?

Julie M. Vose, MD, MBA
December 2nd 2025
Article

Rising cancer diagnoses in the US highlight urgent needs for improved oncology education, workforce distribution, and care infrastructure, especially in rural areas.

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Daniel C. McFarland, DO;Louis P. Voigt, MD;Yesne Alici, MD
November 24th 2025
Podcast

Daniel C. McFarland, DO, is joined by Louis P. Voigt, MD, and Yesne Alici, MD, who focused on decision-making capacity and patient-centered care.

PAS-004 was deemed safe and tolerable when given in 37 mg capsules, so the trial will proceed to administer the agent in 45 mg capsules.

Cohort 7 of Novel MEK Inhibitor Trial Completed for MAPK Pathway-Driven Tumors

Tim Cortese
November 25th 2025
Article

PAS-004 was deemed safe and tolerable when given in 37 mg capsules, so the trial will proceed to administer the agent in 45 mg capsules.

Experts discussed supportive care and why it should be integrated into standard oncology care.

How Supportive Care Methods Can Improve Oncology Outcomes

Declan Walsh, MD;Denise B. Reynolds, RD;Adam Friedman, MD, FAAD;Daniel C. McFarland, DO;Michelle Fingeret, PhD;Christian J. Nelson, PhD;William S. Breitbart, MD
November 10th 2025
Podcast

Experts discussed supportive care and why it should be integrated into standard oncology care.

Novel Agent Yields Promising Results in MAPK-Associated Solid Tumors

Novel Agent Yields Promising Results in MAPK-Associated Solid Tumors

Ariana Pelosci
November 21st 2025
Article

Partial responses and stable disease were observed with PAS-004 in patients with advanced solid tumors harboring RAS, NF1, or RAF mutations.

Results from the C-POST trial showed that cemiplimab improved DFS vs placebo in patients with CSCC at high risk of recurrence following surgery and radiation.

EC Approves Adjuvant Cemiplimab in CSCC at High Risk of Recurrence

Tim Cortese
November 20th 2025
Article

Results from the C-POST trial showed that cemiplimab improved DFS vs placebo in patients with CSCC at high risk of recurrence following surgery and radiation.